Esperion Therapeutics Inc (NAS:ESPR)
$ 2.12 0.12 (6%) Market Cap: 415.99 Mil Enterprise Value: 472.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 53/100

Esperion Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 09, 2020 / 07:00PM GMT
Release Date Price: $27.76 (+9.92%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Okay. Hey, everybody. I'm Marty Auster. I am the lead SMID cap biotech analyst here at Crédit Suisse. You are joining us for the Esperion presentation at the 29th Annual Crédit Suisse Healthcare Conference in the first, and hopefully, the only virtual health care conference we'll be hosting.

I've got Tim Mayleben, CEO; and Rick Bartram, CFO, on the call today. And Tim, Rick, thanks a lot for joining us. Really happy to have you here.

I'll let you kick off and say hi, and you can tell us what it was like trying to launch a drug during the pandemic.

Timothy M. Mayleben
Esperion Therapeutics, Inc. - President, CEO & Director

Yes. Thanks, Marty. Thank you for hosting us today and definitely look forward to a nice conversation here this afternoon. I think maybe I'll just start out by saying, no denying, this has been a challenging unprecedented environment. I think we've exhausted superlatives and adjectives to describe what the COVID

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot